Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

Find out more

Latest News

BioInfect Conference - Redx joins industry leaders to combat one of the biggest threats to global health
10 November 2015

Redx Pharma is pleased to be participating today at BioInfect, the major one day conference bringing together industry leaders to focus on the threat of antimicrobial resistance and the critical issues relating to the development of new anti-infectives.

Antimicrobial resistance (AMR) is an increasingly serious global public health issue that threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. Redx is working in collaboration with the NHS to tackle AMR, and the Group's anti-infectives subsidiary has one of the biggest research teams in the UK, if not Europe, developing the next generation of antibiotics.

Read more

We're Hiring

As a fast-growing dynamic business we are continually looking for talented people to join our team.

Work for us

Investor News

22 June 2015

Announcing our maiden unaudited results for the six months ended 31 March 2015.

Investor Resources

Our Subsidiary Companies

Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.

View details

Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.

View details

Applying our proprietary method to deliver multiple development candidates across a range of mechanistic approaches in cancer treatment.

View details